Our recent study identified non-APL AML blasts having an inversion of chromosome 16 and the presence of CBFB-MYH11 fusion transcripts as sensitive to ATRA in vitro40, but no such conventional diagnostic markers can be used to identify low dose AraC sensitive patients. Here, MYH11 is linked to acute promyelocytic leukemia.